帕立骨化醇预处理对大鼠肝缺血再灌注损伤的作用  

Pretreatment effect of Paricalcitol on hepatic ischemia-reperfusion injury in rats

作　　者：郝立校[1] 蔡珍福[1] 周玉坤[1] 王坚[1] 陈莉[1] 

机构地区：[1]中国人民解放军第四五五医院肝胆外科,上海200052

出　　处：《肝胆胰外科杂志》2016年第1期51-54,共4页Journal of Hepatopancreatobiliary Surgery

基　　金：解放军第455医院院内课题(2014YG003)

摘　　要：目的探讨帕立骨化醇预处理对大鼠肝缺血再灌注损伤的保护作用及合理剂量。方法 300只健康雄性SD大鼠随机分为:假手术组、模型组、实验1组、实验2组、实验3组,每组60只,各实验组分别于肝缺血再灌注手术前24 h腹腔注射0.15、0.30、0.60μg/kg帕立骨化醇。每组取20只大鼠于术后3、6、12和24 h取尾静脉血,并观察各组此20只大鼠术后24、48、72 h的生存率。各组另40只大鼠分别于术后3、6、12、24 h每个时间点处死10只大鼠,取肝组织。比较各组大鼠存活率和术后谷丙转氨酶(ALT)、谷草转氨酶(AST)及肝脏组织丙二醛(MDA)含量。结果模型组大鼠存活率低于假手术组(P<0.05),实验各组大鼠存活率高于模型组;除实验1组与模型组相比无统计学意义外,其余各实验组在术后3、6、12、24 h与模型组相比ALT均有下降(P<0.05);而术后3 h起实验1、2、3组AST水平均低于模型组(P<0.05)。术后3、6、12、24 h,各实验组肝组织MDA均低于模型组,实验2组和3组与实验1组差异具有统计学意义(P<0.05),实验2组与实验3组间差异无统计学意义(P>0.05)。结论帕立骨化醇预处理对大鼠肝缺血再灌注损伤具有保护作用,0.15μg/kg即可以明显改善模型肝功和肝脏MDA水平,但0.30μg/kg以上水平效果更佳。Objective To explore the pretreatment effect of paricalcitol on hepatic ischemia reperfusion damage and explore reasonable dosage. Methods Three hundred healthy male SD rats were randomly divided into sham group （n=60）, model group （n=60）, test 1 group （n=60）, test 2 group （n=60） and test 3 group （n=60）. Rats of test group were intraperitoneal injection with 0.15 μg/kg, 0.30 μg/kg, 0.60 μg/kg of Paricalcitol respectively 24 h before reperfusion. Twenty rats＇ venous blood samples were taken at 3, 6, 12, 24 h after operation in each group, and the survival rates were observed at 24 h, 48 h, 72 h after operation. Ten of the other forty rats were sacrificed for liver tissue at 3, 6, 12, 24 h after operation in each group. All groups of rats were compared with the survival rates, levels ofALT, AST and MDA in liver tissue. Results The survival rate in model group was lower than that in sham group （P〈0.05）, survival rate of all test groups 1, 2 and 3 was significantly lower than that in model group （P〈0.05）. Except test group 1, ALT levels of test 2 and 3were lower than that in model group 3 h postoperative （P〈0.05）. Levels of AST in test group were lower than the model group 3 h postopera- tively （P〈0.05）. Levels of MDA in liver tissue in test groups 1, 2 and 3 were lower than model group 3-24 h postoperatively. Levels of MDA in liver tissue test group 2 and 3 showed statistically difference （P〈0.05） with that in test group 1, but levels of MDA in liver tissue showed no significant difference between test group 2 and 3 （P〉0.05）. Conclusion Paricalcitol pretreatment possesses protective effects on hepatic ischemia-reperfusion injury. Dosage of 0.15 μg/kg can obviously improve the model and hepatic MDA level, and more than 0.30 μg/kg level affects better.

关 键 词：帕立骨化醇 肝脏缺血再灌注损伤 谷丙转氨酶 谷草转氨酶 丙二醛 

分 类 号：R575[医药卫生—消化系统] R453.9[医药卫生—内科学]